University of Illinois at Urbana-Champgain, 23andMe, Michael J. Fox Foundaton for Parkinson's Research, Parkinson's Institute and Clinical Center, SeqWright, Roche NimbleGen, Chronix Biomedical, Genome Atlantic, Agilent Technologies
Working to enroll thousands of individuals with Parkinson's into an online community, Sergey Brin, 23andMe, the Michael J. Fox Foundation, and the Parkinson's Institute are teaming up to offer 23andMe services at a bargain price.
The web-based CollabRx One program, which will charge cancer patients between $50,000 and $100,000 to generate genetically-targeted treatment options, compares 15,000 genes against tumor samples to gauge how they respond to as many as 5,000 drugs.
On its website, the company informs customers that its service tests for the i4000377, i4000378, and i4000379 SNPs in BRCA1 and BRCA2 genes, either one of which may “influence your carrier status for breast/ovarian cancer.”
Navigenics’ lower-priced program to incorporate genetic risk data in patients’ annual medical checkup raises questions as to whether personal genomics firms should be broadly marketing their services to physicians.
Details of the deal are sparse, but the partners said they hope their research will lead to the development of genetic tests that can gauge patients’ predisposition to rare diseases and help target individuals most likely to respond to drugs made by MondoBiotech.